Matt Bottomley

Pablo Zuanic

Vivien Azer

- InterCure Ltd. announced the **strategic acquisition of Botanico Ltd., also known as ISHI**, a premium medical cannabis technology and brand company, on September 19, 2025.  **[1857030_0001493152-25-014152_ex99-1.htm:0]** **[1857030_0001493152-25-014152_ex99-2.htm:0]** 
- This acquisition provides InterCure with **immediate access to advanced cultivation technologies** and established partnerships with leading American cannabis operators, including The Flowery, positioning InterCure to capitalize on the evolving U.S. cannabis market.  **[1857030_0001493152-25-014152_ex99-1.htm:0]** 
- The transaction is structured as a **two-phase acquisition of 100% of ISHI**, with the initial closing expected in **Q1 2026**, subject to regulatory approvals.  **[1857030_0001493152-25-014152_form6-k.htm:1]** **[1857030_0001493152-25-014152_ex99-1.htm:1]** 
- The **total consideration** for the acquisition is **4,513,663 ordinary shares** and **410,599 options** of InterCure, representing approximately **10%** of InterCure's outstanding shares on a fully diluted basis prior to the initial closing.  **[1857030_0001493152-25-014152_form6-k.htm:1]** **[1857030_0001493152-25-014152_ex99-1.htm:1]** 
- ISHI founders **Omer Layani (CEO) and Dor Hershkovitz (COO) will join InterCure's leadership team** as part of the acquisition.  **[1857030_0001493152-25-014152_form6-k.htm:1]** **[1857030_0001493152-25-014152_ex99-1.htm:1]**

Intercure (INCR)